This incredible responsibility means every decision and action we take is guided by integrity and quality. Kenvue’s chief people officer, chief corporate affairs officer, chief technology and data officer, chief scientific officer and group presidents for different regions around the world are also from J&J. Each of the three divisions was profitable on an adjusted operating income basis, the company said in the filing.

It isn’t an attractive option for growth investors, and while the dividend could be relatively high out of the gate, the risk the company faces with respect to talc liabilities negates those positives for me. Investors who are interested in owning the stock may want to see how the company does in its first few quarters before buying shares of the business to see how it performs, as there’s certainly no rush to buy it now. In its prospectus, Kenvue says it holds “leadership positions” in the consumer health market, owning top brands in pain management (Tylenol), facial care (Neutrogena), mouthwash (Listerine), and many other categories. The benefit for investors is that the business has some brand power, which in turn could give it pricing power and make it a potentially resilient company to invest in amid inflation. Strong diversification is one of the things investors can expect to get from owning the healthcare stock.

If you’ve heard of Kenvue, you may already know that we’re a global consumer health company. But beyond our portfolio of iconic brands, Kenvue is built on a foundation of core values, which fuel our 22,000+ global team members every day. J&J faces thousands of allegations that its talc baby powder and other talc products caused cancer.

1. With leading science and knowledge, we educate and empower — so that when people need us, they can rely on our brands.
2. Kenvue (KVUE -0.53%) began trading as a stand-alone business and gives healthcare investors a new stock to potentially add to their portfolios.
3. J&J announced the split in late 2021 as a bid to streamline operations and refocus on its pharmaceutical and medical device divisions.
4. Kenvue’s debut also marks the largest restructuring in J&J’s 135-year history.
5. You should view the Media section in order to receive the most current information made available by Kenvue.

That’s why our iconic brands have helped generations take care of themselves and their loved ones for more than 135 years. We’re driven to win for those we serve, and when we care fiercely for them and one another, we can deliver the best possible care. Together, we create an inclusive place where we can bring our whole selves.

We’re working to improve the sustainability of our products, packaging and operations to build lasting positive change for people, communities and the one planet we call home. For example, the creation of BAND-AID® Brand HYDRO SEAL™ acne blemish patches was born out of viral social media skincare trends. The development of this product demonstrates how Kenvue boldly pursues innovative ways to work, creating solutions that can genuinely improve people’s lives.

Tylenol® launches two new pain solutions being showcased at PAINWeek Conference

Assuming that is the case and the company pays every quarter, that would result in a yield of around 3.1% based on a share price of $26, which would be higher than the S&P 500 average of 1.7%. Thibaut Mongon, J&J’s executive vice president and worldwide chair of consumer health, will serve as CEO of the newly public company. And products in the essential health division, including baby products, mouthwash and dental rinses, sanitary protection and wound care, saw $4.6 billion in net sales, representing 31% of all-in revenue. The spinoff, the biggest IPO since EV maker Rivian went public in November 2021, alone may not completely turn around the moribund IPO market, which plummeted in 2022. Our skin health & beauty brands bring together next-generation science and partnerships with skin experts to create high-performance products for healthy skin.

Paul Ruh, J&J’s chief financial officer of consumer health and a former PepsiCo executive, will serve as CFO, and Meredith Stevens, J&J’s worldwide vice president of the company’s consumer health supply chain department, will serve as COO. Our self-care brands offer new ways for consumers to take the power of their health into their own hands with over-the-counter medicines and naturally inspired solutions. One thing investors will like about the stock is that Kenvue stated in its prospectus that it expects to pay a quarterly cash dividend of $0.20 per share later this year.

In May 2023, Kenvue made our debut as a public company on the New York Stock Exchange, trading under the KVUE ticker symbol. Today, Kenvue is the world’s largest pure-play https://www.forex-world.net/software-development/devops-engineer-weroad/ consumer health company by revenue, with annual sales of ~$15 billion in 2022. This site is governed solely by applicable U.S. laws and governmental regulations.

Kenvue declares quarterly cash dividend

The company’s self-care unit, which includes products for eye care, cough and cold, and vitamins, generated $6 billion in net sales for 2022, accounting for 40% of total revenue. We are committed to continuously improving our sustainability efforts through our brands, packaging and operations, delivering on the expectations of today’s consumers. We’ve always believed in the power of new perspectives and insights to drive innovation.

World Oral Health Day: Level up your oral hygiene routine

The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation. Meanwhile, Kenvue is chock full of household names familiar to investors and the larger public, such as Tylenol, Band-Aid, Listerine, Aveeno, Neutrogena, and J&J’s namesake baby powder and shampoo. The company expected to price 151 million shares between $20 and $23 per share, according to a preliminary prospectus it filed with the Securities and Exchange Commission last week. Our Healthy Lives Mission strives to advance the well-being of both your health and the planet’s health.

J&J spinoff Kenvue prices IPO at $22, toward the top end of expected range

Ten of Kenvue’s brands had approximately $400 million or more in sales last year. Annual sales growth through 2025 is projected to be about 3% to 4% globally, according to the filing. Kenvue is profitable and expects modest growth over the next few years, the company said in the filing. Until then, Kenvue will qualify as a “controlled https://www.topforexnews.org/brokers/antony-tan-joins-is-prime-hong-kong-from-invast/ company” under the corporate governance rules of the NYSE, the filing said. That will allow Kenvue to avoid certain listing standards, including a requirement that the company’s board be composed of a majority of independent directors. J&J plans to distribute the remaining shares of common stock to its shareholders later this year.

From best practices to best-in-class products, we learn, test, partner and optimize. Then we move fast to bring real solutions into communities, homes and hands. With leading science and knowledge, we educate and empower — so that when people need us, they can rely on our brands. Kenvue has already been involved in seven talc lawsuits (at least) since the start of last month, according to Reuters. The danger is that even a handful of claims could potentially yield devastating results for Kenvue, as its assets and revenue stream won’t nearly be the size of Johnson & Johnson’s.

We’re the same iconic brands you know and can trust, backed by more than 135 years of research and development, now housed under a dedicated umbrella of continuous innovation. Our top priority is helping you serve your patients and drive better health outcomes. That’s not necessarily a negative, as it will mean plenty of incentive for the company to be run prudently because Johnson & Johnson will still have a lot of skin in the game.

That means less risk-taking and perhaps more conservatism, which caters to the preferences of dividend investors rather than to those looking for an aggressive growth stock. Although Kenvue is technically a separate company, Johnson & Johnson will still play a big role in its operations; the healthcare company will own a 90% stake in the business. Kenvue’s debut also marks the largest restructuring in J&J’s 135-year history. best js framework for net mvc developer J&J announced the split in late 2021 as a bid to streamline operations and refocus on its pharmaceutical and medical device divisions. With empathy, we unearth extraordinary breakthroughs in everyday care, and with courage and conviction, we bring them to life. We boldly pursue more innovative ways of working, pioneer solutions that improve lives, and create products that create categories — then improve them again and again.

Our committed collaboration fuels our relentless external competitive drive — because the stronger our bonds are, the stronger our brands are, too. Our essential health brands have been raising standards of personal care across baby care, wound care, oral care and sanitary protection for generations. But while that diversification will add safety, it won’t necessarily make for a good growth investment. Kenvue projects that its top line will grow at a compounded annual growth rate of between 3% and 4% through 2025. That again highlights why the business might make more sense for risk-averse dividend investors than for those seeking attractive growth opportunities. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.